Whereas we have been able to show that statins (atorvastatin) decrease circulating 27HC levels in breast cancer patients it was also demonstrated that within the tumors of treated patients there was a compensatory increase in the expression of HMG-CoA reductase, CYP27A1, and decreased expression of reverse cholesterol transporters26. This evidence concerns the gene CYP27A1 and breast carcinoma.